Skip to main content

USPTO Publishes Five RNAi-Related Patent Applications: Feb 22, 2007

Title: Functional and Hyperfunctional siRNA
Number: 20070039072
Filed: March 29, 2005
Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)
According to the patent application’s abstract, “efficient sequence specific gene silencing is possible through the use of siRNA technology. By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene silencing reagent, as well as methods for silencing genes.”

Title: Cell-Signaling Genes and Related Methods
Number: 20070039071
Filed: June 16, 2006
Lead Inventor: Shujun Chang, ArborGen
The patent application, its abstract states, covers “novel plant cell signaling genes and gene products. … These gene, polypeptide, and oligonucleotide sequences are useful in regulating plant phenotype. Moreover, these genes and gene products are useful for expression profiling of plant cell signaling genes. The invention specifically provides polynucleotide and polypeptide sequences isolated from Eucalyptus and Pinus species,” the abstract adds.

Title: Compositions and Methods for siRNA Inhibition of Angiogenesis
Numbers: 20070037762, 20070037761, and 20070037760
Filed: June 8, 2006
Lead Inventor: Michael Tolentino, University of Pennsylvania (Acuity Pharmaceuticals)
“RNA interference using small interfering RNAs, which are specific for the vascular endothelial growth factor gene and the VEGF receptor genes Flt-1 and Flk-1/KDR, [inhibits] expression of these genes,” the patent application’s abstract states. “Diseases which involve antiogenesis stimulated by overexpression of VEGF, such as diabetic retinopathy, age-related macular degeneration, and many types of cancer, can be treated by administering the small interfering RNAs.”

The Scan

Not Kept "Clean and Sanitary"

A Food and Drug Administration inspection uncovered problems with cross contamination at an Emergent BioSolutions facility, the Wall Street Journal reports.

Resumption Recommendation Expected

The Washington Post reports that US officials are expected to give the go-ahead to resume using Johnson & Johnson's SARS-CoV-2 vaccine.

Canada's New Budget on Science

Science writes that Canada's new budget includes funding for the life sciences, but not as much as hoped for investigator-driven research.

Nature Papers Examine Single-Cell, Multi-Omic SARS-CoV-2 Response; Flatfish Sequences; More

In Nature this week: single-cell, multi-omics analysis provides insight into COVID-19 pathogenesis, evolution of flatfish, and more.